Collaborative Arrangement, Achievement Levels of Commercial Performance, Period

No definition available.

Name:	exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
Namespace Prefix:	exel_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement

+ References

No definition available.

+ Details

Name:	exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Maximum amount eligible for commercial milestones under collaborations agreement.

+ References

No definition available.

+ Details

Name:	exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone Payments Earned

+ References

No definition available.

+ Details

Name:	exel_MilestonePaymentsEarned
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percent of royalty on net sale.

+ References

No definition available.

+ Details

Name:	exel_PercentOfRoyaltyOnNetSale
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent

+ References

No definition available.

+ Details

Name:	exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Tier

+ References

No definition available.

+ Details

Name:	exel_RoyaltyTier
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront Payment(s)

+ References

No definition available.

+ Details

Name:	exel_UpfrontPayments
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exel_RoyaltyTierAxis=exel_FinalTierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exel_RoyaltyTierAxis=exel_InitialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exel_RoyaltyTierAxis=exel_SecondMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements (Ipsen Collaboration, Narrative) (Details) - Collaborative arrangement with Ipsen		1 Months Ended	6 Months Ended	12 Months Ended		35 Months Ended
	Dec. 30, 2017 USD ($)	Feb. 29, 2016 USD ($)	Jun. 29, 2018 USD ($)	Dec. 28, 2018 USD ($)	Dec. 28, 2018 CAD ($)	Dec. 28, 2018 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration period to achieve specified levels of commercial performance				10 years	10 years
Upfront payment(s)		$ 210,000,000
Milestone payments earned				$ 140,000,000		$ 275,000,000
Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement		84,000,000
Maximum amount eligible for commercial milestones under collaborations agreement		$ 519,500,000
Remaining performance obligation				$ 48,000,000		48,000,000
Research and development arrangement performed for others, reimbursement for costs incurred, percent				35.00%	35.00%
Net contract liability				$ 13,300,000		$ 13,300,000
Collaborative Arrangement with GlaxoSmithKline
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale				3.00%	3.00%
Final tier
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty tier			$ 150,000,000		$ 30,000,000.0
Initial
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale			2.00%
Second
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale			12.00%
Minimum \| Final tier
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale				22.00%	22.00%
Maximum \| Final tier
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale				26.00%	26.00%
EMA Filing Acceptance - HCC \| Adjustments Due to the Adoption of Topic 606 \| ASU 2014-09
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments earned	$ 10,000,000